Vaxcyte Inc PCVX

Vaxcyte Inc is an American biotechnology and pharmaceutical company based in Foster City, California. Founded in 2013, the firm is primarily engaged in the development of potentially superior and novel vaccines for a variety of infectious diseases. It aims to serve the healthcare community and patients worldwide, helping to prevent and treat some of the most common deadly diseases.

The firm trades on the NASDAQ GS where its stock is listed under the ticker PCVX. In December 2020 the PCVX price chart was showing a 52 week high of $58.48 and a 52 week low of $17.80, with a market cap of $1.55bn.

The company's lead programme is a board-spectrum pneumococcal conjugate vaccine (PCV) which is designed to provide expanded protection for patients, against currently circulating strains of pneumococcus. Other vaccines in the pipeline are being designed to protect against Invasive Pneumococcal Disease, Otitis Media, Group A Strep Infections and Periodontitis. The company is developing novel vaccines and vaccines that are potentially more effective than those currently available to help prevent and treat disease in millions of people across the globe.

Consider diversifying your investments today by adding PCVX stock to your eToro portfolio, or track this instrument via your watchlist.